Baumii Sanghuang

Metadata

Regulatory Status

South Korea

• Health functional food: P. baumii extracts are marketed in South Korea as health functional food products under the Korean Health/Functional Food Act (MFDS). Products include capsules, tablets, and liquid extracts.
• Cultivation status: Large-scale artificial cultivation of P. baumii fruiting bodies has been achieved in Korea, making it commercially accessible. It is one of the most widely cultivated sanghuang species in East Asia.
• Traditional medicine (Hanbang): Sang Hwang (sanghuang) has been an important mushroom in Korean traditional medicine for centuries, valued for immune support, cancer adjunctive therapy, and general health promotion. Han et al. (2016) confirmed that the species extensively used as “sanghuang” in Korea is P. baumii (= I. baumii), not the tropical P. linteus as previously assumed.
• Note: The pharmaceutical product Mesima (approved in Korea for cancer adjunctive immunotherapy) is derived from P. linteus mycelium, not P. baumii. These are distinct species with different chemistries.

China

• Traditional use: Known as “Sanghuang” in Chinese medicine, used for strengthening health and prolonging life. However, Chinese sanghuang traditionally refers to species growing on mulberry (Morus) trees, which corresponds to Sanghuangporus sanghuang rather than P. baumii (which grows on Syringa).
• Chinese Pharmacopoeia: Not separately listed. The sanghuang complex has not been formally codified in the Chinese Pharmacopoeia.

Japan

• Health food: Available as a health supplement in Japan. Japanese researchers have contributed significantly to the chemical characterization of styrylpyrone compounds from P. baumii.

United States

• Dietary supplement: Products containing sanghuang or P. baumii are available as dietary supplements under DSHEA. Species identity verification is a concern, as sanghuang products may contain multiple Sanghuangporus/Phellinus species.
• Not FDA-approved as a drug.

European Union

• Not recognized: No specific regulatory status in the EU.

Conditions & Indications

Primary Indications (Preclinical Evidence)

• Immune modulation and immune restoration — P. baumii ethanol extract enhanced immune response in cyclophosphamide-induced immunosuppressed mice, promoting proliferation of splenocyte T and B lymphocytes, restoring peritoneal NK cell activity, and stimulating cytokine secretion (Lee et al. 2019). Water-soluble polysaccharides demonstrated direct macrophage activation and immunostimulatory activity.
• Anti-inflammatory activity — Multiple compound classes from P. baumii inhibit inflammatory pathways:
  • Polysaccharide SHPS-1 decreased STAT-1 phosphorylation and inflammatory gene expression; alleviated ulcerative colitis in mice (Sun et al. 2021)
  • Ethyl acetate extract inhibited LPS-induced iNOS, COX-2, and proinflammatory cytokine expression in macrophages via NF-kB and MAPK signaling (Ullah et al. 2021)
  • Phenolic compounds showed NF-kB inhibitory activity in LPS-stimulated RAW264.7 cells (Lee et al. 2017)

Secondary Indications (Preclinical Evidence)

• Hepatoprotection — Polysaccharide fraction PPB-2 prevented increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in liver-injury mouse models, reduced total cholesterol, triglycerides, total bilirubin, and hepatic malondialdehyde levels, while enhancing antioxidant enzyme activities and glutathione levels (Zheng et al. 2019).
• Antidiabetic / hypoglycemic effects — Phenolics from cultivated P. baumii fruiting bodies demonstrated alpha-glucosidase and alpha-amylase inhibitory activities and showed significant inhibition of glucose diffusion. In type 2 diabetic mice, P. baumii phenolics reduced blood glucose and improved metabolic parameters (Jia et al. 2021). A separate study identified cultivated P. baumii as a potentially sustainable antidiabetic resource (Wang et al. 2020).
• Antioxidant and DNA protection — Polysaccharide PPB-2 exhibited noticeable antioxidant activity and strong protection against oxidative DNA damage in Fenton reaction and comet assay models (Lim et al. 2016).

Emerging/Preclinical Indications

• Antitumor activity — A 17-kDa water-soluble polysaccharide from P. baumii suppressed HepG2 human liver cancer cell proliferation in a dose-dependent manner, caused cell cycle arrest at the S phase, and induced apoptosis (Song et al. 2010). P. baumii polyphenols also demonstrated therapeutic potential against lung cancer cells (Park et al. 2022).
• Anti-influenza activity — Five polyphenols from P. baumii (hispidin, hypholomine B, inoscavin A, davallialactone, phelligridin D) noncompetitively inhibited neuraminidase from H1N1, H5N1, and H3N2 influenza strains and reduced virally-induced cytopathic effects in MDCK cells (Lee et al. 2015).
• Anti-platelet activity — Reported in preclinical models, suggesting cardiovascular protective potential.
• Anti-obesity effects — Reported as a biological activity in preliminary studies.

Mechanism of Action

Primary Mechanisms

1. Polysaccharide-driven immune activation P. baumii polysaccharides, particularly the PPB-2 fraction and SHPS-1, activate innate immune cells through mechanisms shared across the Hymenochaetaceae family:

• Enhanced macrophage proliferation and cytokine production
• Restoration of T and B lymphocyte proliferation in immunosuppressed states
• NK cell activity enhancement
• STAT-1 pathway modulation for anti-inflammatory immunoregulation

2. Styrylpyrone pharmacology (species-distinctive) P. baumii produces a distinctive class of styrylpyrone compounds that differentiate it chemically from many other medicinal polypores:

• Baumin — A novel styrylpyrone first isolated from P. baumii, with antioxidant activity via iron chelation and free radical scavenging
• Hispidin — A styrylpyrone pigment shared with P. linteus, demonstrating antioxidant, anti-inflammatory, and antitumor activities
• Davallialactone — A dimeric styrylpyrone with potent NF-kB inhibitory and antioxidant activity
• Phelligridins — Styrylpyrone derivatives (D, H) with anti-inflammatory and antioxidant properties
• Phellibaumins A-E — Five novel hispidin derivatives unique to P. baumii

These styrylpyrone compounds provide antioxidant protection through a dual mechanism: Fenton reaction inhibition via iron chelation and direct free radical scavenging.

3. NF-kB and MAPK pathway inhibition Multiple extract fractions from P. baumii converge on NF-kB and MAPK signaling pathway inhibition:

• Ethyl acetate extract: inhibits NF-kB nuclear translocation and MAPK phosphorylation (p38, ERK, JNK) in CFA-induced inflammation models
• Phenolic metabolites: direct NF-kB inhibitory activity
• Polysaccharide SHPS-1: modulates inflammatory gene expression through STAT-1 pathway

4. Carbohydrate-hydrolyzing enzyme inhibition Polysaccharides and phenolics from P. baumii inhibit alpha-glucosidase and alpha-amylase, slowing carbohydrate digestion and glucose absorption. This mechanism parallels pharmaceutical alpha-glucosidase inhibitors (acarbose) used in type 2 diabetes management.

Secondary Mechanisms

• Neuraminidase inhibition: Polyphenols noncompetitively inhibit influenza neuraminidase, a mechanism shared with the pharmaceutical oseltamivir (Tamiflu)
• Cell cycle arrest and apoptosis induction: Polysaccharides cause S-phase arrest and apoptosis in hepatocarcinoma cells
• Hepatoprotective antioxidant activity: PPB-2 enhances hepatic antioxidant enzymes (SOD, GSH) and reduces lipid peroxidation (MDA)

Key Active Compounds

Clinical Evidence Summary

No clinical trials have been conducted specifically on molecularly verified P. baumii material. However, clinical trials on “sanghuang” or P. linteus in Korea may have included P. baumii material due to widespread misidentification.

Key Preclinical Studies

Taxonomic Identification Studies

Evidence Limitations

• No clinical trials specifically on P. baumii. Clinical trial data for sanghuang in Korea (e.g., the Mesima pharmaceutical) pertain to P. linteus, not P. baumii.
• Widespread taxonomic confusion means that some literature attributed to P. linteus or “sanghuang” may actually involve P. baumii material, and vice versa.
• The distinction between P. baumii (lilac host), S. sanghuang (mulberry host), and P. linteus (tropical, mulberry/hardwood host) was only clarified in recent years, complicating retrospective evidence attribution.
• Most in vivo studies use mouse models with short treatment durations and small sample sizes.
• Anti-influenza neuraminidase inhibition is demonstrated in vitro; in vivo and clinical antiviral efficacy is unknown.

Safety Profile

General Assessment

P. baumii has been consumed as a traditional medicine and health food in Korea and China for centuries, suggesting a generally favorable safety profile. No serious adverse events have been reported in the literature. Toxicity studies in mice suggest a safe dose of up to 1 g/kg body weight, though human-equivalent dosing extrapolation requires caution.

Contraindications

• Autoimmune disease: Immunostimulatory polysaccharide activity may exacerbate autoimmune conditions.
• Organ transplant recipients: Immunomodulatory effects may interfere with immunosuppressive regimens.
• Pregnancy and lactation: No safety data. Avoid.
• Pre-surgical: Potential antiplatelet activity warrants discontinuation 2 weeks before elective surgery (precautionary).

Drug Interactions

• Immunosuppressants (cyclosporine, tacrolimus): Immunostimulatory activity may counteract immunosuppressive therapy. Severity: Moderate (inferred from mechanism).
• Antidiabetic agents (metformin, acarbose): Additive hypoglycemic effects possible due to alpha-glucosidase inhibition and glucose-lowering phenolics. Severity: Low-to-moderate. Monitor blood glucose.
• Anticoagulants/antiplatelets: Potential additive antiplatelet effects. Severity: Low (precautionary).
• Influenza antivirals (oseltamivir): Theoretical additive neuraminidase inhibition; clinical significance unknown. Severity: Theoretical.

Side Effects

• No adverse event reports specifically documented for P. baumii in published literature.
• Based on the broader sanghuang/Phellinus experience: gastrointestinal discomfort is possible.

Clinical Dosage

No standardized human dosage exists specifically for P. baumii. The following information draws on traditional Korean use, preclinical studies, and reference doses from related sanghuang species.

Dried Fruiting Body

• Traditional dose: 3-9 g/day as decoction, simmered for 1-2 hours
• Korean practice: Fruiting body pieces are traditionally boiled in water for prolonged periods to prepare a dark, concentrated tea

Extract (Capsule/Tablet)

• Reference dose (from sanghuang clinical trials): 500 mg capsule twice daily (1,000 mg/day total), based on a P. linteus protocol adapted to general sanghuang dosing
• Note: This dose was used in a P. linteus clinical trial protocol; direct applicability to P. baumii is assumed but unverified

Mycelial Culture Extract

• Submerged liquid fermentation products are commercially available in Korea
• Dose guidelines vary by manufacturer; standardization is not established

Special Consideration

• Cultivated P. baumii is commercially available in Korea and China and is generally preferred over wild-harvested material for consistency of bioactive compound content.
• Species verification is critical: P. baumii (lilac host), S. sanghuang (mulberry host), and P. linteus (tropical) have different chemical profiles. Products labeled generically as “sanghuang” may contain any of these species.

Sources

• Han JG, Hyun MW, Kim CS, et al. Species identity of Phellinus linteus (sanghuang) extensively used as a medicinal mushroom in Korea. J Microbiol. 2016;54(4):290-295
• Dai YC, Cui BK, Zhou LW, et al. Addressing widespread misidentifications of traditional medicinal mushrooms in Sanghuangporus (Basidiomycota) through ITS barcoding and designation of reference sequences. IMA Fungus. 2021;12:10
• Lee IK, Kim YS, Jang YW, Jung JY, Yun BS. Styrylpyrones from the medicinal fungus Phellinus baumii and their antioxidant properties. Bioorg Med Chem Lett. 2010;20(17):5459-5461
• Lee HJ, Kang JS, Kim YI, et al. Anti-influenza activities of polyphenols from the medicinal mushroom Phellinus baumii. Bioorg Med Chem Lett. 2015;25(16):3256-3260
• Lee JW, Baek SJ, Lee TS. Anti-inflammatory phenolic metabolites from the edible fungus Phellinus baumii in LPS-stimulated RAW264.7 cells. Molecules. 2017;22(10):1583
• Lee JH, Kim BG, Kim S, et al. Phellinus baumii enhances the immune response in cyclophosphamide-induced immunosuppressed mice. Nutr Res. 2019;75:53-63
• Song Y, Hui J, Kou W, et al. Immunostimulatory and anti-tumor activity of a water-soluble polysaccharide from Phellinus baumii mycelia. World J Microbiol Biotechnol. 2010;27(5):1017-1023
• Zheng W, Zhao Y, Zhang M, et al. Characterization and biological activities of polysaccharides from artificially cultivated Phellinus baumii. Int J Biol Macromol. 2019;129:1134-1145
• Lim BO, Lee SH, Park DK, Choue RW. Antioxidant and DNA damage protecting potentials of polysaccharide extracted from Phellinus baumii using a delignification method. J Medicinal Food. 2016;19(9):870-876
• Sun KL, Xia HS, Zhang ZH, et al. Chemical structure and anti-inflammatory activity of a branched polysaccharide isolated from Phellinus baumii. Carbohydr Polym. 2021;268:118214
• Ullah S, Khalil AA, Shaukat F, Song Y. Inhibitory effect of Phellinus baumii extract on CFA-induced inflammation in MH-S cells through NF-kB and MAPK signaling pathways. Evid Based Complement Alternat Med. 2021;2021:5535630
• Jia X, Ma L, Li P, et al. Anti-inflammatory properties in vitro and hypoglycaemic effects of phenolics from cultivated fruit body of Phellinus baumii in type 2 diabetic mice. Molecules. 2021;26(8):2285
• Wang L, Li P, Feng X, et al. Cultivated fruit body of Phellinus baumii: a potentially sustainable antidiabetic resource. ACS Omega. 2020;5(4):2330-2340
• Park JS, Lee HJ, Shin SY, et al. Phellinus baumii polyphenol: a potential therapeutic candidate against lung cancer cells. Molecules. 2022;27(24):8870
• Kim YS, Lee IK, Yun BS. Chemical constituents from the fungus Phellinus baumii and their anti-inflammatory activity. Mycobiology. 2022;50(5):306-314
• Zhu L, Song Y, Liu H, et al. Research progress of bioactive components in Sanghuangporus spp. Molecules. 2024;29(6):1195
• Lee IK, Yun BS. Styrylpyrone-class compounds from medicinal fungi Phellinus and Inonotus spp., and their medicinal importance. J Antibiot. 2011;64(5):349-359

Connections

• Compare with Phellinus linteus (Meshimakobu / Sang Hwang), which has stronger clinical evidence through the Korean pharmaceutical Mesima but is a tropical species distinct from P. baumii; both share hispidin and related polyphenols, but P. baumii uniquely produces baumin and phellibaumins A-E
• Sanghuangporus sanghuang is the species growing on mulberry trees (Morus) that corresponds to the traditional Chinese “Sang Huang” concept; distinct from P. baumii (lilac host) and P. linteus (tropical, various hosts)
• Phellinus igniarius is another member of the broader sanghuang complex with overlapping traditional uses but distinct chemistry
• The anti-influenza neuraminidase inhibition by P. baumii polyphenols connects to emerging antiviral medicinal mushroom research; compare with the broader immunomodulatory antiviral approach of Turkey Tail and Reishi
• The alpha-glucosidase inhibitory activity parallels findings in Ganoderma resinaceum, suggesting convergent metabolic support pharmacology across distantly related polypore lineages
• The immunostimulatory polysaccharide mechanism (macrophage activation, NK cell enhancement, T/B lymphocyte proliferation) is shared across the Hymenochaetaceae and Ganodermataceae families, connecting P. baumii to the broader beta-glucan immunology of Turkey Tail, Meshima, and Reishi
• The taxonomic confusion within sanghuang species underscores the critical importance of molecular identification in medicinal mushroom research and commerce, paralleling the Ganoderma lucidum species complex taxonomy issues